BioSpace News Archive

Aditxt, Inc. announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock at a purchase price of $1.22 per share priced at-the-market under Nasdaq rules.

Vyant Bio, Inc. is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Trinity Biotech plc announced that on April 19, 2023 the Company received notice from the Nasdaq Stock Market LLC that the Company is not in compliance with Nasdaq Listing Rule 555, as the minimum bid price of the Company’s American depositary shares has been below US $1.00 per share for 30 consecutive business days.

Center for Pain Management, together with American Pain Consortium, is the first Interventional Pain clinic in the country to perform a trial of the new and first-of-its kind Spinal Cord Stimulator (SCS) called The Prospera™ Spinal Cord Stimulation System with Embrace One™ through Biotronik Neuro, Inc.

Samsung Bioepis Co., Ltd. today announced that 1-year outcomes of the Phase 3 study for SB15, a proposed biosimilar to Eylea1(aflibercept), were presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from April 23 to 27, in New Orleans, Louisiana.

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2022.

Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in New Orleans.

NASDAQ IVCP Swiftmerge Acquisition Corp announced the signing of a non-binding letter of intent for a business combination with HDL Therapeutics Inc., a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in homozygous familial hypercholesterolemia patients.

Texas Biomedical Research Institute’s 3rd Global Health Symposium on May 18 and 19 will convene experts from across the nation and the world to discuss how community, trust and science can help build health equity.

QIAGEN announced that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a single patient sample.